Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Marginal zone lymphoma (MZL) is challenging to treat, with many patients relapsing following initial treatment. We report the long-term efficacy and safety of copanlisib, a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, in the subset of 23 patients with relapsed/refractory MZL treated in th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Panayiotidis, Panayiotis, Follows, George A., Mollica, Luigina, Nagler, Arnon, Özcan, Muhit, Santoro, Armando, Stevens, Don, Trevarthen, David, Hiemeyer, Florian, Garcia-Vargas, Jose, Childs, Barrett H., Zinzani, Pier Luigi, Dreyling, Martin
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2021
Schlagworte:
Lymphoid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7876879/
https://ncbi.nlm.nih.gov/pubmed/33560394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002910
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge